Epidemiology indicates a gender disparity in GBMs [8,48,49,50]: the Central Brain Tumor Registry of the United States (CBTRUS) statistical report of central nervous system tumors (2017–2021) evidences an increased prevalence of GBM IDH-wt in males (1.6 times more prevalent) than in females, with a median survival duration of 15.0 months in male patients, versus 25.5 months in female patients [51,52]. Here, IDH2 is linked to brain neoplasm.